Effect of insomnia in the major depressive disorder

Xu, Guohong; Li, Xiaoling; Xu, Caixia; Xie, Guojun; Liang, Jiaquan

doi:10.1186/s12883-022-02869-x

Cited by 9 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, insomnia is a risk factor for new onset as well as recurrent episodes of depression (Franzen & Buysse, 2008 ) Comorbid depression and insomnia increase the duration and severity of depression while increasing the likelihood of depression relapse (Franzen & Buysse, 2008 ). A 2022 study indicated that the prognosis for MDD is poor in patients with co‐morbid insomnia (Franzen & Buysse, 2008 ; Xu et al., 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study

Tellone,

Markovic,

Strashimirova

et al. 2024

Brain and Behavior

View full text Add to dashboard Cite

BackgroundHealth‐related quality of life (HRQL) is an important goal for patients with major depressive disorder (MDD), but whether antidepressants improve HRQL in these patients is unclear. Here, we describe the real‐world effects of trazodone once‐a‐day (TzOAD) and selective serotonin reuptake inhibitor (SSRI) treatments on HRQL and functioning in adults with MDD.MethodsThis 8‐week prospective, observational, open‐label, multicenter study was conducted in adults with moderate or severe MDD for whom TzOAD or SSRI were prescribed as monotherapy. The primary outcome was life enjoyment and satisfaction assessed via the patient‐reported Quality‐of‐Life Enjoyment and Satisfaction Questionnaire Short Form (Q‐LES‐Q‐SF) from baseline to week 8. Secondary outcomes included change in Q‐LES‐Q‐SF from baseline to weeks 1 and 2; severity of depressive symptoms using the Montgomery Åsberg Depression Rating Scale (MADRS) and sleep disturbance via the PROMIS SF‐SD 8b questionnaire at weeks 1, 2, and 8; and overall functioning via the Sheehan Disability Scale (SDS), hedonic capacity using the Snaith–Hamilton Pleasure Scale (SHAPS), and cognitive dysfunction using the Perceived Deficits Questionnaire (PDQ‐5) at baseline and week 8.ResultsThe study included 208 adults with MDD (mean [SD] age = 50.2 [14.3] years; 68.6% female; 98.4% White). Life enjoyment and satisfaction improved from baseline to week 8 for both treatment groups: Q‐LES‐Q‐SF mean (SD) scores were 27.5 (20.4) for the SSRI group and 39.0 (22.1) for the TzOAD group. Depressive symptoms and sleep disturbances also reduced from baseline to week 8: MADRS (SSRI, −15.7 [8.3]; TzOAD, −21.0 [9.8]); PROMIS SF‐SD 8b (SSRI, −9.9 [12.6]; TzOAD, −22.0 [12.6]). Mean change scores in Q‐LES‐Q‐SF, MADRS, and PROMIS SF‐SD 8b improved as early as week 1 in both groups. Mean scores also improved from baseline to week 8 on SDS (SSRI, −9.2 [7.4]; TzOAD, −14.3 [7.5]), SHAPS (SSRI, −6.6 [4.3]; TzOAD, −8.3 [4.4]), and PDQ‐5 (SSRI, −5.8 [4.5]; TzOAD, −7.7 [5.0]).ConclusionsIn adults with MDD who received TzOAD or SSRIs, overall and individual HQRL domains improved rapidly and in parallel with improvements in depressive symptoms, with a slightly greater improvement observed in the TzOAD group.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study

Tellone,

Markovic,

Strashimirova

et al. 2024

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…Ndufb11 plays a significant role within CI, contributing to the production of energy in the mitochondria [24] the survival and normal function of cells. [25,26] Particularly, diseases related to mitochondrial dysfunction may be associated with mutations or functional abnormalities in Ndufb11. These diseases may include mitochondrial disorders, neuromuscular diseases, among others, and research into these conditions helps to better understand the role of Ndufb11 in mitochondrial function.…”

Section: Discussionmentioning

confidence: 99%

NDUFB11 and NDUFS3 regulate arterial atherosclerosis and venous thrombosis: Potential markers of atherosclerosis and venous thrombosis

Ma,

Yang,

et al. 2023

Medicine

View full text Add to dashboard Cite

Atherosclerosis is a chronic disease that thickens the blood vessel walls and narrows the lumen. Venous thrombosis is a blood clot that forms in the body’s deep veins or pulmonary arteries. However, the relationship between NDUFB11 and NDUFS3 and atherosclerosis and venous thrombosis is unclear. We employed data files that combined atherosclerosis and chronic stress groups. Subsequently, we conducted differential gene expression analysis (DEGs) and performed weighted gene co-expression network analysis (WGCNA). We constructed and analyzed a protein-protein interaction (PPI) network. Further analyses included functional enrichment analysis, gene set enrichment analysis (GSEA), gene expression heatmaps, immune infiltration analysis, and mRNA analysis. By comparing our findings with the Comparative Toxicogenomics Database (CTD), we identified the most relevant diseases associated with the core genes. Additionally, we utilized TargetScan to screen for miRNAs regulating the central DEGs. To validate our results, we conducted Western Blot experiments at the cellular level. A total of 1747 DEGs were co-identified. According to the Gene Ontology (GO) analysis of differentially expressed genes, they were primarily enriched in mitochondrial gene expression, mitochondrial envelope, organelle membrane, and mitochondrial inner membrane categories. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the target cells were mainly enriched in metabolic pathways, ribosomes, and histidine metabolism. The intersection of enriched terms from both GO and KEGG analyses showed significant enrichment in mitochondrial gene expression, mitochondrial envelope, organelle inner membrane, ribosomal structural constituents, histidine metabolism, and oxidative phosphorylation. Eight core genes were identified, including NDUFS5, UQCRQ, COX6C, COX7B, ATP5ME, NDUFS3, NDUFA3, and NDUFB11. The gene expression heatmap demonstrated that core genes (NDUFB11 and NDUFS3) were downregulated in atherosclerosis with venous thrombosis samples and upregulated in normal samples. CTD analysis revealed that the core genes NDUFB11 and NDUFS3 were associated with pain, arterial diseases, atherosclerosis, arteritis, venous thrombosis formation, and venous thromboembolism. We added Western Blot basic cell experiment for verification. NDUFB11 and NDUFS3 are downregulated in atherosclerosis and venous thrombosis, associated with poorer prognosis, and may serve as potential biomarkers for both diseases.

show abstract

“…Insomnia can lead to excessive daytime sleepiness, emotional instability, and may also trigger a series of health problems such as depression, anxiety, cognitive decline, and an increased risk of chronic diseases. [3][4][5] Insomnia disorder is defined as a subjective report of dissatisfaction with the sleep duration and/or quality, despite adequate opportunities and circumstances for sleep, which impacts daytime social functioning. 6 Currently, clinical diagnosis of insomnia disorder relies primarily on patients' subjective complaints.…”

Section: Introductionmentioning

confidence: 99%

Wavelet Entropy Analysis of Electroencephalogram Signals During Wake and Different Sleep Stages in Patients with Insomnia Disorder

Yang,

Liu,

Wang

et al. 2024

NSS

View full text Add to dashboard Cite

Objective To investigate the changes in the wavelet entropy during wake and different sleep stages in patients with insomnia disorder. Methods Sixteen patients with insomnia disorder and sixteen normal controls were enrolled. They underwent scale assessment and two consecutive nights of polysomnography (PSG). Wavelet entropy analysis of electroencephalogram (EEG) signals recorded from all participants in the two groups was performed. The changes in the integral wavelet entropy (En) and individual-scale wavelet entropy (En(a)) during wake and different sleep stages in the two groups were observed, and the differences between the two groups were compared. Results The insomnia disorder group exhibited lower En during the wake stage, and higher En during the N3 stage compared with the normal control group (all P < 0.001). In terms of En(a), patients with insomnia disorder exhibited lower En(a) in the β and α frequency bands during the wake stage compared with normal controls (β band, P < 0.01; α band, P < 0.001), whereas they showed higher En(a) in the β and α frequency bands during the N3 stage than normal controls (β band, P < 0.001; α band, P < 0.001). Conclusion Wavelet entropy can reflect the changes in the complexity of EEG signals during wake and different sleep stages in patients with insomnia disorder, which provides a new method and insights about understanding of pathophysiological mechanisms of insomnia disorder. Wavelet entropy provides an objective indicator for assessing sleep quality.

show abstract

Effect of insomnia in the major depressive disorder

Cited by 9 publications

References 29 publications

Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study

Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study

NDUFB11 and NDUFS3 regulate arterial atherosclerosis and venous thrombosis: Potential markers of atherosclerosis and venous thrombosis

Wavelet Entropy Analysis of Electroencephalogram Signals During Wake and Different Sleep Stages in Patients with Insomnia Disorder

Contact Info

Product

Resources

About